Melanotan II activates melanocortin receptors involved in skin pigmentation and sexual response. It is used for tanning and is also associated with erection effects.
What Melanotan II does and why that matters
Melanotan II activates melanocortin receptors. In people, early studies found that it can darken skin pigment and can also trigger erections; nausea, fatigue and prolonged erections were among the observed effects. Its practical appeal is tanning or sexual response without sun exposure or a blood-flow drug, but it is not an approved cosmetic or sexual-health treatment and long-term safety is not established. [1,6]
Function evidence: Small early human studies; routine cosmetic safety unestablished
What people may notice and what remains unknown
Melanotan II is different from compounds supported only by animal research: very small human studies did record visible pigmentation and erections in selected participants. The tanning pilot enrolled three men, and the erection study involved ten men with psychogenic erectile dysfunction. Those findings help explain why users report noticeable effects, but they cannot predict a typical response or establish safe routine use. Nausea, fatigue and prolonged erections occurred in early research, product strength can be inconsistent, and long-term cosmetic use has not been adequately studied. [1,2,6,7]
What supports this description: Very small human studies with observable effects; long-term safety unknown
Melanotan II Dosing status
Dose: No safe routine cosmetic tanning dose established by these sources. | Frequency: No validated home-use schedule. | Cycle: No established cosmetic loading or maintenance cycle. | Route: Early studies used subcutaneous injections. This is study context, not an instruction. [1,2]
Preparation: No patient preparation recipe supported here..
Experimental study dosing is not a home-use protocol. TGA advises stopping Melanotan II tanning products. This page does not supply dilution, injection or storage instructions. [1,2,6]
Melanotan II Effects
Pigmentation pilot. A 1996 study enrolled three healthy men. Two showed increased pigmentation when assessed one week after dosing ended. This small pilot cannot predict a typical user's result or establish long-term safety. [1]
Erection study. A placebo-controlled crossover study in ten men with psychogenic erectile dysfunction recorded erections in eight after Melanotan II. This selected population does not establish a general libido benefit or a treatment for routine use. [2]
Melanotan II Side Effects
Short-term study effects. Nausea, yawning, stretching and erections occurred in the small studies; the pilot also reported fatigue or sleepiness. These samples cannot provide reliable side-effect rates for routine use. [1,2]
Serious toxicity reports. One case report describes systemic toxicity and muscle breakdown after self-injection. FDA also lists reports of priapism, neurological harm and melanoma. Reports identify concerns, not their frequency or proof of causation in every case. [3,5]
Moles and melanoma uncertainty. TGA warns about mole and freckle changes. A published melanoma case involved both Melanotan II and sunbed use, so it cannot establish that the peptide alone caused the cancer. [4,7]
Unreliable product strength. In 2026, TGA tested five bottles of one nasal-spray product labelled 30 mg. Estimated amounts ranged from 22 to 54 mg per labelled bottle volume. This is a finding about those samples, not a survey of all products. [6]
Frequently Asked Questions About Melanotan II
Does skin darkening mean Melanotan II is safe?
No. A pigmentation result in a small study cannot establish long-term safety. TGA warns against these tanning products. A tan is not a substitute for sun protection. [1,6,7]
Does Melanotan II cause melanoma?
A reported melanoma case also involved sunbed exposure. It raises a concern but does not prove causation or measure risk. FDA includes melanoma among serious events reported with Melanotan II. [4,5]
Is a nasal spray a safe alternative?
TGA's 2026 testing found inconsistent strength in five bottles of one nasal spray and warns against Melanotan II tanning products. Avoiding a needle does not establish product safety. [6]
Is there a recommended loading dose?
The cited studies do not establish a safe routine tanning dose, loading cycle or maintenance plan. TGA advises stopping tanning products containing Melanotan II, rather than adjusting their dose. [1,2,6]
Evidence
Small human studies; serious safety concerns. The cited pigmentation pilot enrolled three men. It does not establish a safe cosmetic tanning regimen. FDA and Australia's TGA flag safety concerns. [1,5,6]
Approval status: Not approved as a tanning agent in Australia; TGA warns against use. [6]
References
Dorr RT et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study Life Sci, 1996. PMID 8637402
Wessells H et al. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study Journal of Urology, 1998. PMID 9679884
Nelson ME et al. Melanotan II injection resulting in systemic toxicity and rhabdomyolysis Clin Toxicol (Phila), 2012. PMID 23121206
Hjuler KF et al. Melanoma associated with the use of melanotan-II Dermatology, 2014. PMID 24355990
U.S. Food and Drug Administration Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks , . Source
Therapeutic Goods Administration Melanotan II tanning peptide products found to be inconsistently dosed , 2026. Source
Educational evidence summary. Approval applies only to the named product and indication; compounded, investigational, and research-market products are different categories.
◇An FDA-approved label or a patient-specific prescription from a licensed pharmacy
◇The active ingredient, strength, dosage form, concentration, lot, and dispensing instructions
◇Identity or purity tests only support the tests performed; they do not prove sterility, endotoxin safety, dose accuracy, stability, or clinical suitability
◇A “research use only” vial is not a patient medicine
